MOUNTAIN VIEW, CA--(MARKET WIRE)--Aug 30, 2006 -- Broncus Technologies, Inc. announced today that it has closed a $29.5 million round of Series F venture funding from a broad, international syndicate of new and existing investors, including Abingworth, Biomedical Sciences Investment Fund, Bio-Star, HBM BioCapital, HBM BioVentures, Japan Asia Investment Co (JAIC), Menlo Ventures, Pac-Link, Rockport Ventures, Saratoga Ventures and Sightline Ventures.
Timothy Haines, Partner at new investor Abingworth, said, “We are delighted to be investing in Broncus, a company that Abingworth considers to be a leader in the emerging Interventional Bronchoscopy field. We are impressed by the clinical experience of Broncus’ novel products to treat emphysema and look forward to supporting the company through the pivotal US clinical study.”
“We are privileged to have such a high caliber group of investors, and would like to welcome Abingworth, JAIC and Saratoga as new investors in Broncus,” said Cary Cole, President & CEO. “We will utilize these funds to complete the company’s IDE pivotal study and start market development activities.”
About Broncus Technologies, Inc.
Broncus has developed an investigational bronchoscopic procedure for the treatment of emphysema. See http://www.broncus.com for more information.
Contact: Contact: Mark Caires (650) 428-1600
Source: Broncus Technologies, Inc.
